---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-058594"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2025-12-22T23:59:59+00:00"
generated_at: "2026-05-16T12:24:07.219862+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Vistagen's PALISADE-3 Phase 3 study of fasedienol fails primary endpoint in social anxiety disorder

## Summary
- LS mean change from baseline on SUDS score: fasedienol 13.6 (SE 1.54) vs placebo 14.0 (SE 1.51); no statistical significance.
- Secondary endpoints also showed no treatment difference between fasedienol and placebo.
- Favorable safety data consistent with prior trials; no new safety signals.
- Phase 3 failure likely halts development path for intranasal fasedienol in acute social anxiety.

## SEC filing metadata
- accession: 0001628280-25-058594
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2025-12-22T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000162828025058594/0001628280-25-058594-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000162828025058594/vtgn-20251217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-058594
- JSON: https://secwatch.observer/filing/0001628280-25-058594.json
- Plain text: https://secwatch.observer/filing/0001628280-25-058594.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.